Influenza vaccine prevents medically attended influenza-associated acute respiratory illness in adults aged ≥50 years.

BACKGROUND There are few estimates of effectiveness influenza vaccine in preventing serious outcomes due to influenza in older adults. METHODS Adults aged ≥50 years who sought medical care for acute respiratory illness were enrolled. A nose/throat swab was tested for influenza virus by reverse transcription-polymerase chain reaction. Clinical and demographic data were collected, including verification of receipt of trivalent inactivated influenza vaccination (IIV-3). Adjusted odds ratios were estimated by multivariable logistic regression models with an L1 penalty on all covariates except vaccination status. RESULTS A total of 1047 subjects were enrolled from November through April during 5 influenza seasons during 2006-2012, excluding the 2009-2010 season. Of those enrolled, 927 (88%) had complete influenza virus testing, vaccination status, and demographic data obtained. Of 86 (9.3%) influenza virus-positive patients, 47 (55%) were vaccinated. Of 841 influenza virus-negative patients, 646 (76.8%) were vaccinated. Over 5 influenza seasons, IIV-3 was 58.4% effective (95% confidence interval [CI], 37.0%-75.6%) for the prevention of medically attended laboratory-confirmed influenza illness in adults aged ≥50 years and 58.4% effective (95% CI, 7.9%-81.1%) in adults aged ≥65 years. CONCLUSIONS Influenza vaccine was moderately effective in preventing influenza-associated medical care visits in older adults.

[1]  H. Kelly,et al.  Effectiveness of seasonal trivalent inactivated influenza vaccine in preventing influenza hospitalisations and primary care visits in Auckland, New Zealand, in 2013. , 2014, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[2]  H. Kelly,et al.  The effectiveness of seasonal trivalent inactivated influenza vaccine in preventing laboratory confirmed influenza hospitalisations in Auckland, New Zealand in 2012. , 2014, Vaccine.

[3]  A. Monto,et al.  Interim Estimates of 2013–14 Seasonal Influenza Vaccine Effectiveness — United States, February 2014 , 2014, MMWR. Morbidity and mortality weekly report.

[4]  F. Pozo,et al.  Vaccine effectiveness in preventing laboratory-confirmed influenza in Navarre, Spain: 2013/14 mid-season analysis. , 2014, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[5]  O. Garin,et al.  Influenza vaccine effectiveness in preventing outpatient, inpatient, and severe cases of laboratory-confirmed influenza. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  L. Rosella,et al.  Vaccine Effectiveness Against Laboratory-Confirmed Influenza Hospitalizations Among Elderly Adults During the 2010–2011 Season , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  Qingxia Chen,et al.  Effectiveness of influenza vaccine for preventing laboratory-confirmed influenza hospitalizations in adults, 2011-2012 influenza season. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  S. Wisniewski,et al.  Interim Adjusted Estimates of Seasonal Influenza Vaccine Effectiveness — United States, February 2013 , 2013, MMWR. Morbidity and mortality weekly report.

[9]  S. Wisniewski,et al.  Early Estimates of Seasonal Influenza Vaccine Effectiveness — United States, January 2013 , 2013, MMWR. Morbidity and mortality weekly report.

[10]  A. Monto,et al.  Effectiveness of seasonal influenza vaccines in the United States during a season with circulation of all three vaccine strains. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  N. Voirin,et al.  Influenza vaccine effectiveness among adult patients in a University of Lyon hospital (2004-2009). , 2012, Vaccine.

[12]  J. Castilla,et al.  Vaccine effectiveness in preventing influenza hospitalizations in Navarre, Spain, 2010-2011: cohort and case-control study. , 2012, Vaccine.

[13]  A. Monto,et al.  Effectiveness of Non-Adjuvanted Pandemic Influenza A Vaccines for Preventing Pandemic Influenza Acute Respiratory Illness Visits in 4 U.S. Communities , 2011, PloS one.

[14]  M. Valenciano,et al.  Early estimates of seasonal influenza vaccine effectiveness in Europe, 2010/11: I-MOVE, a multicentre case-control study. , 2011, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[15]  Qingxia Chen,et al.  Effectiveness of seasonal vaccine in preventing confirmed influenza-associated hospitalizations in community dwelling older adults. , 2011, The Journal of infectious diseases.

[16]  M. Valenciano,et al.  Estimates of Pandemic Influenza Vaccine Effectiveness in Europe, 2009–2010: Results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) Multicentre Case-Control Study , 2011, PLoS medicine.

[17]  Trevor Hastie,et al.  Regularization Paths for Generalized Linear Models via Coordinate Descent. , 2010, Journal of statistical software.

[18]  G. Dinant,et al.  Mortality benefits of influenza vaccination in elderly people. , 2008, The Lancet. Infectious diseases.

[19]  Yi Guan,et al.  Three Indonesian clusters of H5N1 virus infection in 2005. , 2006, The New England journal of medicine.

[20]  E. Walsh,et al.  Respiratory syncytial virus infection in elderly and high-risk adults. , 2005, The New England journal of medicine.

[21]  H. Zou,et al.  Regularization and variable selection via the elastic net , 2005 .

[22]  G. Dinant,et al.  The Efficacy of Influenza Vaccination in Elderly Individuals: A Randomized Double-blind Placebo-Controlled Trial , 1994 .

[23]  A. Kumar,et al.  Three Indonesian Clusters of H5N1 Virus Infection in 2005 , 2008 .

[24]  A R Hinman,et al.  Field evaluation of vaccine efficacy. , 1985, Bulletin of the World Health Organization.